Shaping the future of obesity care
Over the last few years, GLP-1 and next-generation anti-obesity medicines have moved from specialist care into one of the most important global health trends. These treatments can deliver clinically meaningful weight loss, and the category is expected to grow significantly in the coming years.
20%+
weight loss now achievable with modern treatments.
A major problem is being solved — and a new support need is emerging.
Modern obesity treatments work partly by reducing appetite and calorie intake. Total calorie intake may fall by 16–39%, which is central to weight loss — but it also changes the gut environment. Less food intake, altered nutrient patterns, delayed gastric emptying and common digestive side-effects create new needs around gut health, digestive comfort, nutritional resilience and long-term wellbeing.
That is why Azento Health is developing azh-biotics® — a microbiome-based companion platform designed to support people before, during and after their weight-loss journey.
Our ambition
To help shape the next generation of modern obesity care: science-led, gut-health focused, and built around the real needs of patients, consumers and healthcare professionals.
Open to collaboration
We welcome companies, clinics, pharmacies, researchers and healthcare organisations who share this ambition — in distribution, product development, research collaboration, clinical projects or companion solutions for modern obesity treatments.
The gut science behind modern weight loss
azh-biotics® is a microbiome-based technology companion platform designed to support people before, during and after weight-loss treatments.
Professor Arne Astrup
MD, DMSc (DK) · Scientific advisor
“I am excited to be part of Azento Health, as their approach for supporting GLP-1 patients is unique. Their microbiome-focused solutions represent a significant contribution to patient health and well-being.”
“Since I together with Professor Jens Holst in 1996 discovered GLP-1 as being a satiety hormone in humans, I have been working with GLP-1s. I look forward to contributing to Azento Health’s mission.”
01
Addressing gut microbiome imbalances that are common in obesity and may worsen with rapid weight loss.
02
Reducing gastrointestinal side-effects and improving overall gut health to enhance treatment success.
03
Enabling better metabolic outcomes, weight maintenance and long-term health through nutritional and microbiome-focused solutions.
Our platform focuses on gut health, digestive comfort, microbiome resilience, nutrition routines and long-term Health & Happiness. We are developing an ambitious pipeline of 10+ products and concepts across the full patient journey — both under our own brand and in collaboration with partners.
The next phase of obesity care needs more than powerful medicines. It needs support that fits the real patient journey.
Expert perspective
“Azento Health’s focus on gut health, tolerability, nutrition and long-term metabolic resilience addresses an important need in modern obesity care. The azh-biotics scientific platform brings an evidence-driven microbiome approach to supporting people on modern anti-obesity medications along their treatment journeys.”
“Having worked across clinical care, academia and global drug development in diabetes and obesity, I have seen how transformative therapies reach their full potential when patients are supported throughout the treatment journey.”
Professor Stephen Gough, MD FRCP (UK)
Clinician and pharmaceutical leader in diabetes, obesity and GLP-1-based therapies
Modern obesity care is evolving. Let’s build the support category together.
For health and happiness
